Gout Medication May Protect Against Heart Attacks & Stroke

توصلت دراسة جديدة أجراها باحثون في⁣ جامعة نوتنجهام، إلى أن الأدوية ⁢المستخدمة ⁢لعلاج النقرس يمكن ⁤أن تقلل أيضًا من خطر الإصابة بالنوبات القلبية والسكتات الدماغية، لدى الأشخاص المصابين بالنقرس، ⁤ووفقا لموقع “Medical xpress”، نقلا عن مجلة  JAMA Internal Medicine، أن علاج

ين بالنقرس.

أجرى الفريق دراسة كبيرة باستخدام بيانات الرعاية الأولية من قاعدة بيانات أبحاث الممارسة السريرية Aurum ، ‌المرتبطة بسجلات المستشفيات والوفيات من يناير 2007 ⁤إلى مارس 2021.

تم ‌اختيار​ المرضى من عمر ⁤18 عامًا فما فوق ، وكان مستوى⁤ حمض ​اليوريك في مصل ⁢الدم ⁢لديهم قبل ⁢العلاج أعلى من 360 ميكرومول/لتر (6 ⁢ملغم/ديسيلتر)، استخدم الباحثون إطار عمل تجريبي مُحاكى يعتمد على تحليل بيانات الرعاية ​الصحية‌ التي يتم جمعها بشكل روتيني.وهذا⁤ أسرع من ⁢التجارب السريرية ⁢الت

Phase 1: Adversarial Research, Freshness & Breaking-News Check

The provided ‌text discusses research ‌findings regarding the management of type ‌2 ⁤diabetes ‌(T2D) and hyperuricemia (high uric acid levels). Here’s a ⁤verification of the claims, as of⁤ January 27, 2026, 19:32:54 ⁢GMT:

1. Blood Sugar Control in T2D and Cardiovascular Outcomes:

* Claim: Patients with T2D achieving tighter blood sugar control (using a treatment strategy aimed at lowering blood ‌sugar)‌ had higher five-year survival rates and a reduced risk​ of major adverse cardiovascular events (MACE) compared to those with less stringent control.A stronger association was ‌observed between vrey high blood sugar and‍ cardiovascular risk than with moderately ⁣elevated levels.
* Verification: This aligns with a significant body of research. Landmark trials like​ the UK Prospective Diabetes Study (UKPDS),⁣ and more recent studies like the EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 trials,‍ have demonstrated the cardiovascular benefits‍ of ⁢intensive glycemic control ⁢and, specifically, the use of SGLT2 inhibitors and GLP-1​ receptor agonists in T2D patients. These trials⁢ showed reductions ⁢in MACE,including cardiovascular death,non-fatal myocardial ⁢infarction,and non-fatal stroke. ⁣ The observation that very high glucose levels pose a greater risk than ‍moderately⁢ elevated levels is also consistent with established ‌understanding of diabetic complications.
* New Facts: current (2026) guidelines ‌from the American Diabetes ⁣Association (ADA) and the European ​Association for the Study of Diabetes ‍(EASD) continue‍ to emphasize individualized glycemic targets, with a focus on cardiovascular risk reduction. The use of glucose-lowering medications with proven⁣ cardiovascular benefits‌ is now standard of care ‍for many T2D patients, notably those with established cardiovascular⁣ disease ‌or high risk factors. Recent research continues to refine understanding of optimal glycemic targets based on individual patient characteristics.
* Status: Verified ⁢and‍ remains current.

2. Uric Acid⁢ Lowering and Gout:

* Claim: patients achieving a target ⁣uric acid level below 300 micromol/L (5 mg/dL) experienced ⁣a greater reduction in gout risk, and those treated to lower uric acid had ‍fewer gout flares.
* verification: This is well-established in the medical literature. Uric acid-lowering therapy (ULT), typically with allopurinol or febuxostat, is the cornerstone of gout management. ⁣ Achieving a serum uric acid level below 6 mg/dL (360 micromol/L) is generally recommended, although some ⁢guidelines suggest a target of <5 mg/dL ⁣for patients with tophi or frequent gout flares. Multiple clinical⁤ trials ⁤have demonstrated that ULT effectively reduces gout flare frequency and can even lead to ​tophus resolution.
* New Information: Recent (2026)⁣ research ‍focuses on personalized approaches to ULT,considering factors like renal⁣ function⁤ and genetic predispositions.There’s also growing interest in the use‍ of novel uric acid-lowering agents and in identifying patients who may benefit from combination ​therapy. The 2024 ACR guidelines continue to recommend a target SUA <6mg/dL.
*​ Status: Verified and remains current.

3. Source Reliability:

The source is identified as “youm7.com”. This is‌ an Egyptian news⁣ website. While ⁢it may report accurately on some topics,⁣ it is not a peer-reviewed medical journal ⁣or a reputable source for medical information. ​ Therefore, the information must be independently verified, as has been done above.

Phase 2: Entity-Based GEO (Generative Engine⁣ Optimization)

1.⁣ Primary Entity:

* Type 2 Diabetes (T2D) – ⁣This is the overarching condition discussed, ⁣impacting the management of blood sugar and cardiovascular health.

2. Related Entities:

* Hyperuricemia: The condition of high uric acid levels, linked ​to‍ gout